| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
4-Vinylsyringol targets COX-2 (cyclooxygenase-2), showing potential as a COX-2 inhibitor. As a phenolic compound, it exhibits potent antioxidant, anti-inflammatory, and anticancer properties. The compound's antioxidant activity involves neutralizing free radicals and protecting against oxidative stress-related diseases. It modulates cellular signaling pathways. Its anti-inflammatory activity is mediated through COX-2 inhibition. The compound's phenolic structure provides hydrogen donors for radical scavenging and interactions with inflammatory targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 4-Vinylsyringol exhibits antioxidant activity and inhibits lipid peroxidation. The compound shows potential as a COX-2 inhibitor. It exhibits potent antioxidant, anti-inflammatory, and anticancer properties. Its ability to neutralize free radicals and protect against oxidative stress has been characterized. These in vitro findings support its potential applications in pharmaceutical, nutraceutical, and material chemistry research.
|
| ln Vivo |
In vivo studies of 4-Vinylsyringol are limited as the compound is primarily used as a research chemical. Its antioxidant, anti-inflammatory, and anticancer properties suggest potential for in vivo evaluation in models of oxidative stress, inflammation, and cancer. As a phenolic compound, it would be absorbed and metabolized through standard xenobiotic pathways. However, comprehensive in vivo pharmacological studies specifically targeting 4-Vinylsyringol are not well documented. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for 4-Vinylsyringol typically involve testing its COX-2 inhibitory activity. Enzyme activity is measured using appropriate substrates and detection methods. Antioxidant activity is assessed using cell-free systems such as DPPH radical scavenging assays, ABTS assays, or ferric reducing antioxidant power (FRAP) assays. Lipid peroxidation inhibition is measured using standard assays. The compound's purity and identity are confirmed using analytical chemistry methods. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays for 4-Vinylsyringol involve culturing cells to evaluate its antioxidant, anti-inflammatory, and anticancer activities. Cells are treated with varying concentrations of the compound and exposed to oxidative stress inducers. Reactive oxygen species levels are measured using fluorescent probes. For anti-inflammatory studies, cells are stimulated with inflammatory stimuli and cytokine production is measured. For anticancer studies, cancer cell lines are treated and cell viability is assessed. All experiments are performed with appropriate controls.
|
| Animal Protocol |
In vivo animal experiments for 4-Vinylsyringol would be conducted to evaluate its antioxidant, anti-inflammatory, and anticancer activities. For antioxidant studies, animals would be administered the compound and markers of oxidative stress measured. For anti-inflammatory studies, animals with induced inflammation would be treated and inflammatory markers measured. For anticancer studies, tumor-bearing animals would be treated and tumor growth monitored. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 4-Vinylsyringol reflect its nature as a small phenolic compound. It has a molecular weight of 180.20 and the molecular formula C10H12O3. As a lipophilic phenolic compound, it would be absorbed through the gastrointestinal tract and distributed throughout the body. The compound is expected to be metabolized through standard xenobiotic pathways in the liver, including conjugation reactions. Complete pharmacokinetic profiling including half-life, clearance, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 4-Vinylsyringol has been evaluated in the context of its use as a research chemical. As a naturally occurring phenolic compound from canola oil, it is expected to have a favorable safety profile at research concentrations. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
4-Vinyleugenol belongs to the phenolic class of compounds and also to the methoxybenzene class of compounds.
4-Vinylsyringol (CAS# 28343-22-8) is also known as 2,6-dimethoxy-4-vinylphenol, canolol. It has the molecular formula C10H12O3 and a molecular weight of 180.20. The compound is a phenolic compound with antioxidant properties and shows potential as a COX-2 inhibitor. It is a flavoring agent extracted from crude canola oil. 4-Vinylsyringol exhibits potent antioxidant, anti-inflammatory, and anticancer properties and inhibits lipid peroxidation. |
| Molecular Formula |
C10H12O3
|
|---|---|
| Molecular Weight |
180.20
|
| Exact Mass |
180.078
|
| CAS # |
28343-22-8
|
| PubChem CID |
35960
|
| Appearance |
White to off-white solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
285.4±35.0 °C at 760 mmHg
|
| Flash Point |
126.4±25.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
1.57
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
156
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C=CC1=CC(OC)=C(O)C(OC)=C1
|
| InChi Key |
QHJGZUSJKGVMTF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12O3/c1-4-7-5-8(12-2)10(11)9(6-7)13-3/h4-6,11H,1H2,2-3H3
|
| Chemical Name |
4-ethenyl-2,6-dimethoxyphenol
|
| Synonyms |
4-Vinylsyringol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (554.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5494 mL | 27.7469 mL | 55.4939 mL | |
| 5 mM | 1.1099 mL | 5.5494 mL | 11.0988 mL | |
| 10 mM | 0.5549 mL | 2.7747 mL | 5.5494 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA